echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > "Science" Third dose of BNT162b2 protects against Omicron variants

    "Science" Third dose of BNT162b2 protects against Omicron variants

    • Last Update: 2022-02-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A new study evaluating the effectiveness of the BNT162b2 (Pfizer Biotech) vaccine against the Omicron variant shows that three doses of the vaccine can provide a sufficient level of protection against disease caused by the Omicron variant
    .


    The globally prevalent SARS-CoV-2 Concern Variant (VOC) Omicron (B.


    "Further clinical trials and real-world data will appear soon to address the efficacy of a third dose of Omicron-mediated BNT162b2 against COVID-19," they concluded




    Magazine

    Science

    DOI

    10.


    Article Title

    Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.